Background and Purpose  We investigated predictors of institutionalization in patients with Alzheimer’s disease (AD) in South Korea.

Methods  In total, 2,470 patients with AD aged 74.5±7.8 years (mean±standard deviation, 68.1% females) were enrolled from November 2005 to December 2013. The dates of institutionalization were identified from the public Long-Term-Care Insurance program in January 2014. We used a Cox proportional-hazards model to identify predictors for future institutionalization among characteristics at the time of diagnosis in 2,470 AD patients. A similar Cox proportional-hazards model was also used to investigate predictors among variables that reflected longitudinal changes in clinical variables before institutionalization in 816 patients who underwent follow-up testing.

Results  A lower Mini Mental State Examination score [hazard ratio (HR)=0.95, 95% confidence interval (CI)=0.92–0.97] and higher scores for the Clinical Dementia Rating and Neuropsychiatric Inventory (HR=1.01, 95% CI=1.00–1.01) at baseline were independent predictors of institutionalization. The relationship of patients with their main caregivers, presence of the apolipoprotein E e4 allele, and medication at baseline were not significantly associated with the rate of institutionalization. In models with variables that exhibited longitudinal changes, larger annual change in Clinical Dementia Rating Sum of Boxes score (HR=1.15, 95% CI=1.06–1.23) and higher medication possession ratio of antipsychotics (HR=1.89, 95% CI=1.20–2.97) predicted earlier institutionalization.

Conclusions  This study shows that among Korean patients with AD, lower cognitive ability, higher dementia severity, more-severe behavioral symptoms at baseline, more-rapid decline in dementia severity, and more-frequent use of antipsychotics are independent predictors of earlier institutionalization.

Key Words  Alzheimer’s disease, institutionalization, Korean.

INTRODUCTION

Dementia, of which Alzheimer’s disease (AD) is the most prevalent type, is the most frequent reason for institutionalization of the elderly.1,2 Approximately 20% of patients are institutionalized within 1 year following a dementia diagnosis, and this proportion increases to 50% after 5 years and approaches 90% after 8 years.3 Many studies have identified predictors of institutionalization in patients with AD.3–12 The severities of cognitive impairment, functional impairment, and behavioral symptoms such as depression or hallucinations at baseline have been found to be reliable and consistent predictors of institutionalization.3,4,6,8 The use of antipsychotics was also found to be associated with earlier institutionalization,4 as were the caregiver being a child or another relative rather than the spouse,3 and the patient not being married.3,6 However, other sociodemographic variables such as age, gender,
Institutionalization in AD

and whether or not the patient lived alone were considered inconclusive.3,4,6,9

Most of the above-mentioned studies were conducted in western countries, with analogous studies evaluating Asian populations being relatively rare.7 The social, cultural, and economic situations in certain Asian populations may affect the decisions both to put a patient on a waiting list for a nursing home and then to actually accept an offered space. One previous Korean study7 that included 79 cases identified 6 predictors of the institutionalization of patients with dementia: 3 patient-related factors [higher scores on the Clinical Dementia Rating (CDR) and Brief Psychiatric Rating Scale, and shorter duration of dementia] and 3 caregiver-related factors (younger age, longer formal education, and higher cost of home care). To the best of our knowledge, no previous studies have investigated the predictors of institutionalization in a large Asian population.

This study evaluated baseline factors at a diagnosis of AD that may predict institutionalization in a large Korean sample (n=2,470). We also applied the same interview and neuropsychological tests as in the baseline evaluation before institutionalization to 816 patients who completed at least one follow-up visit, with the aim of identifying predictors of institutionalization among the variables that reflected longitudinal changes in clinical variables after the diagnosis of AD.

METHODS

Participants were drawn from the Clinical Research Center for Dementia of South Korea (CREDOS) study. The CREDOS study is a nationwide multicenter registry cohort study of dementia that began in November 2005.13 Thirty-one university and general hospitals in South Korea have participated in this study to construct a hospital-based registry of dementia patients. The CREDOS cohort is dynamic, with participants being continually added following diagnoses of subjective memory impairment, mild cognitive impairment, mild cognitive impairment of subcortical vascular type, AD, and subcortical vascular dementia. The included participants must agree to be registered in the cohort, and they are removed from the cohort after being lost to follow-up or due to death.14 In addition, the participants can withdraw voluntarily from the cohort.

Patients

From November 2005 to December 2013 we recruited 3,752 patients from the CREDOS study who had very recently been diagnosed with AD. Because the current study utilized nationwide data from the public Long-Term-Care Insurance (LTCI) program to decide whether the patient is qualified for admission to a nursing home, 1,105 patients who were enrolled in the CREDOS study before July 1, 2008 (when the LTCI program started in South Korea) were excluded. Among the remaining 2,647 patients, 134 patients who had already been institutionalized at the time they were enrolled in the CREDOS study were also excluded. Another 43 patients for whom there was insufficient information were disqualified, finally resulting in the inclusion of 2,470 patients.

In evaluating the apolipoprotein E (APOE) genotype as a predictor of institutionalization, 1,456 patients who had agreed to undergo genetic tests were studied. The diagnostic evaluation of patients and inclusion and exclusion criteria are described in detail elsewhere.13,15 AD was formally diagnosed in accordance with the criteria of probable AD of the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association).16

This study was approved by the Institutional Review Boards of all participating hospitals (AJIRB-CRO-07-95 and AJIRB-MED-SUR-12-27), and written informed consent was obtained from patients and their caregivers after they had received a complete description of the study.

Institutionalization

Institutionalization was defined as admission to long-term-care facilities. In South Korea there are two kinds of long-term-care facilities where elderly people in need of nursing care are traditionally and most commonly admitted: long-term-care hospitals and nursing homes. Nursing homes are licensed nursing facilities that provide 24-hour care and benefit directly from the public LTCI program. Direct medical services are not available in nursing homes, but these facilities maintain connections with community hospitals. On the other hand, long-term-care hospitals are community hospitals where long-term admission is available. Elderly people with a chronic illness such as dementia or stroke are mostly admitted to these hospitals, and usually for several years. Long-term-care hospitals receive funding from National Health Insurance rather than from the public LTCI program.

The date of placement in the nursing home was derived from LTCI program data as at January 1, 2014. For those admitted to long-term-care hospitals, we utilized data from National Health Insurance as at January 1, 2014. Because the data from National Health Insurance does not differentiate between acute-care hospitals and long-term-care hospitals, we regarded the patient as institutionalized when he or she was admitted to and remained in the same hospital for at least 6 months.
Public LTCI for the elderly in South Korea
LTCI has been in effect in South Korea since July 2008. The LTCI program covers the entire population aged 65 years and older regardless of income, and the population younger than 65 years selected based on relatively high levels of severity in the standardized evaluation of senile functional disorders that include dementia, cerebrovascular diseases, and Parkinson’s disease. The Korean LTCI recognizes in-kind benefits in principle, which consist of home-care and residential-care benefits. Home-care benefits include home help, home bathing, home nursing, day/night care, and short-term care, while residential-care benefits consist of elderly care facilities and group homes. There is flexibility in selecting between residential-care and home-care benefits. Institutionalized patients with AD must be qualified in LTCI to receive residential-care benefits. When a patient is admitted, long-term-care facilities report data for that patient to the National Health Insurance Service in order to obtain financial support. Thus, since July 2008 when the LTCI program was introduced, lists of dementia patients admitted to long-term-care facilities could be compiled using data from the National Health Insurance Service.

Baseline demographic and clinical variables
The following variables were included as baseline factors: age, gender, length of formal education, Clinical Dementia Rating Sum of Boxes (CDR-SB) score, Mini Mental State Examination (MMSE) score, Geriatric Depression Scale (GDS) score, total score for the NeuroPsychiatric Inventory (NPI), comorbidities such as hypertension, diabetes mellitus, cardiovascular disease, and stroke, alcohol consumption, and smoking. Other included variables were the relationship with the main caregiver (categorized into spouse, son/daughter-in-law, daughter/son-in-law, or others), APOE genotypes, and medication types [cholinesterase inhibitors (ChEI)/memantine, antipsychotics, and benzodiazepines].

Variables for measuring longitudinal changes
The following variables were obtained for patients who completed at least one follow-up visit using the same interview and neuropsychological tests as applied in the baseline evaluation: annual change in MMSE score, annual change in CDR-SB score, annual change in total NPI score, and medication possession ratio (MPR) of antipsychotics and ChEI or memantine. For participants in whom the MMSE, CDR-SB, or NPI score was evaluated several times, the annual score change was obtained by (score at the last visit minus score at the baseline evaluation/time interval in years between the last visit and the baseline visit). Only the tests performed before institutionalization were included for institutionalized patients, while tests performed up to December 2013 were included for not-institutionalized patients. MPR is calculated by dividing the total number of days of prescription use by the total number of follow-up days for the patient. When calculating the MPR, only the number of days before institutionalization was included for institutionalized patients, while the number of days up to December 2013 was included for not-institutionalized patients. We used MPR to evaluate the medication effect on institutionalization since the medication time can vary between patients. Data for variables related to longitudinal changes during the defined period were available for 816 patients.

Data analysis and statistics
Categorical variables are reported as frequencies and percentages, while continuous variables are reported as mean±standard-deviation values. Discrete variables were compared using chi-square tests. Independent Student’s t-tests were used to compare characteristics between not-institutionalized and institutionalized groups. We implemented three Cox proportional-hazards models. The first Cox proportional-hazards model was used to identify predictors of future institutionalization among characteristics at the time of diagnosis in 2,470 AD patients. We also performed a sensitivity analysis using a similar model that included the CDR instead of CDR-SB as a variable with the same number of subjects. The second Cox proportional-hazards model was applied to 1,456 patients for whom data were available on the APOE genotype and baseline characteristics at the diagnosis of AD. The final Cox proportional-hazards model was used to investigate predictors among variables that reflected longitudinal changes in clinical characteristics prior to institutionalization in 816 patients who underwent follow-up testing.

Cox proportional-hazards models were created to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for incident institutionalization among AD. The time to an event was defined as the time from study entry to the first-time institutionalization. Participants who had not been institutionalized were treated as censored observations on January 1, 2014. All statistical analyses were performed using the Statistical Analysis System (SAS) (version 9.3, SAS Institute, Cary, NC, USA).

RESULTS
Characteristics of the patients
Among the entire cohort of 2,470 patients, 421 patients (17.0%) had been institutionalized in a nursing home (49.2%), long-term-care hospital (44.7%), or both (6.2%) for 38.3±16.5 months. The baseline demographic and clinical variables are
presented in Table 1. Patients who were institutionalized were significantly older (75.4 vs. 74.3 years, \( p=0.005 \)) at baseline and had less education (5.7 vs. 6.4 years, \( p=0.027 \)) than those who were not institutionalized. Institutionalized patients had more-severe dementia according to CDR and MMSE and more-severe neuropsychiatric symptoms (higher NPI score) at baseline than did the patients who were not institutionalized. These two groups did not differ with regard to pathological comorbidities at baseline such as hypertension, diabetes mellitus, and stroke. Regarding medications, those who were institutionalized were taking more antipsychotics at baseline, but the usage of ChEI, memantine, and benzodiazepine did not differ between the two groups.

The 1,456 patients for whom APOE genotyping data were available were younger (73.7 vs. 75.6 years, \( p<0.001 \)) and had more education (6.6 vs. 5.9 years, \( p<0.001 \)), less hypertension \( [n=699 (48.0\%) \text{ vs. } n=546 (53.9\%), \ p=0.004] \), less diabetes mellitus \( [n=335 (23.0\%) \text{ vs. } n=280 (27.5\%), \ p=0.009] \), a less-significant history of stroke \( [n=84 (5.8\%) \text{ vs. } n=116 (11.4\%), \ p<0.001] \), lower CDR-SB score (5.1 vs. 5.7, \( p<0.001 \)), and higher MMSE score (18.5 vs. 17.8, \( p=0.002 \)) than the 1,014 patients without APOE genotyping. The prevalence of the APOE e4 allele did not differ significantly between the institutionalized group \( (n=87, 37.5\%) \) and the not-institutionalized group \( (n=499, 40.8\%; \ p=0.352) \) in the analyses including only the 1,456 patients with APOE geno-

### Table 1. Patient characteristics at baseline

| Variables                     | Overall \( (n=2,470) \) | Institutionalized \( (n=421, \ 17.0\%) \) | Not institutionalized \( (n=2,049, \ 83.0\%) \) | \( p \) |
|-------------------------------|--------------------------|-------------------------------------------|---------------------------------------------|-----|
| Age (year)                    | 74.5±7.8                 | 75.4±7.7                                  | 74.3±7.8                                    | <0.01* |
| Female                        | 1,683 (68.1)             | 300 (71.3)                                | 1,383 (67.5)                                | 0.13 |
| Education (year)              | 6.3±5.1                  | 5.7±4.9                                   | 6.4±5.2                                     | <0.01* |
| Dementia severity and clinical variables |                        |                                           |                                             |     |
| MMSE score                    | 18.2±5.1                 | 16.2±5.1                                  | 18.6±5.0                                    | <0.01* |
| CDR-SB score                  | 5.3±3.0                  | 6.6±3.5                                   | 5.1±2.9                                     | <0.01* |
| NPI score                     | 15.2±18.1                | 20.4±21.8                                 | 14.1±17.1                                   | <0.01* |
| GDS score                     | 7.1±4.4                  | 6.9±4.4                                   | 7.1±4.4                                     | 0.53 |
| Comorbidities                 |                          |                                           |                                             |     |
| Hypertension                  | 1,245 (50.4)             | 197 (46.8)                                | 1,048 (51.2)                                | 0.10 |
| Diabetes mellitus             | 615 (24.9)               | 109 (25.9)                                | 506 (24.7)                                  | 0.60 |
| Cardiovascular disease        | 392 (15.9)               | 62 (14.7)                                 | 330 (16.1)                                  | 0.48 |
| Stroke                        | 200 (8.1)                | 34 (8.1)                                  | 166 (8.1)                                   | 0.98 |
| Alcohol consumption           |                          |                                           |                                             | 0.05 |
| Current                       | 1,310 (78.9)             | 286 (82.7)                                | 1,024 (77.9)                                |     |
| Never                         | 351 (21.1)               | 60 (17.3)                                 | 291 (22.1)                                  |     |
| Smoking                       |                          |                                           |                                             | 0.79 |
| Current smoker                | 134 (8.1)                | 26 (7.5)                                  | 108 (8.2)                                   |     |
| Ex-smoker                     | 336 (20.2)               | 67 (19.4)                                 | 269 (20.5)                                  |     |
| Never smoked                  | 1,191 (71.7)             | 253 (73.1)                                | 938 (71.3)                                  |     |
| Living with main caregiver    | 1,452 (59.1)             | 235 (56.0)                                | 1,217 (59.7)                                | 0.15 |
| Main caregiver                |                          |                                           |                                             |     |
| Spouse                        | 715 (29.2)               | 95 (22.6)                                 | 620 (30.5)                                  |     |
| Son/daughter-in-law           | 927 (37.8)               | 183 (43.6)                                | 744 (36.6)                                  |     |
| Daughter/son-in-law           | 709 (28.9)               | 120 (28.6)                                | 589 (29.0)                                  |     |
| Others                        | 100 (4.1)                | 22 (5.2)                                  | 78 (3.8)                                    |     |
| Medications                   |                          |                                           |                                             |     |
| ChEI/memantine                | 2,114 (89.9)             | 370 (87.9)                                | 1,744 (85.1)                                | 0.14 |
| Antipsychotic                 | 249 (10.1)               | 66 (15.7)                                 | 183 (8.9)                                   | <0.01* |
| Benzodiazepine                | 1,554 (62.9)             | 248 (58.9)                                | 1,306 (63.7)                                | 0.06 |

*Data are mean±standard-deviation or \( n \) (% values).

*\( p<0.05 \) between institutionalized and not-institutionalized patients.

CDR-SB: Clinical Dementia Rating Sum of Boxes, ChEI: cholinesterase inhibitors, GDS: Geriatric Depression Scale, MMSE: Mini Mental State Examination, NPI: NeuroPsychiatric Inventory.
typing.

The 816 patients who underwent follow-up testing were younger (73.3 vs. 75.1 years, \(p<0.001\)) and had a longer total follow-up duration (45.3 vs. 34.9 months, \(p<0.001\)), more education (6.7 vs. 6.1 years, \(p<0.001\)), lower CDR-SB score at baseline (5.0 vs. 5.5, \(p<0.001\)), lower NPI score (13.6 vs. 15.9, \(p=0.001\)), lower GDS score (6.7 vs. 7.2, \(p=0.009\)), and higher MMSE score (18.5 vs. 18.0, \(p=0.020\)) than the 1,654 patients for whom longitudinal changes were not measured. These subjects had a higher usage of ChEI or memantine \([n=720 (88.2\%) \text{ vs. } n=1,394 (84.3\%), p=0.008]\) but a lower usage of benzodiazepines \([n=478 (58.6\%) \text{ vs. } n=1,076 (65.1\%), p=0.001]\) than did those without variables of longitudinal changes. Of the 816 patients who underwent follow-up testing, 130 (16.0%) had been institutionalized for 45.3 ± 13.0 months. Patients who were institutionalized had a significantly larger annual change in CDR-SB score (3.5 vs. 1.6, \(p<0.001\)), larger annual change in MMSE score (-2.9 vs. -1.6, \(p=0.002\)), and higher usage of antipsychotics (MPR=0.4 vs. 0.2, \(p=0.001\)). Sociodemographic variables such as age, gender, length of formal education, and comorbidities (diabetes mellitus, hypertension, cardiovascular disease, and stroke) did not differ between the groups. The NPI score also did not change significantly from baseline to benzodiazepine use (Table 2).

**Predictors of institutionalization**

The multivariate Cox proportional-hazards model with base-

| Table 2. Patient characteristics for variables that were measured longitudinally |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Variables                   | Overall \((n=816)\)         | Institutionalized \((n=130, 16.0\%)\) | Not institutionalized \((n=686, 84.0\%)\) | \(p\)                      |
| Age (year)                  | 73.3±7.9                    | 74.1±8.2                    | 73.2±7.9                    | 0.21                       |
| Female                      | 279 (34.2)                  | 42 (32.3)                   | 237 (24.6)                  | 0.62                       |
| Female                      | 279 (34.2)                  | 42 (32.3)                   | 237 (24.6)                  | 0.62                       |
| Education (year)            | 6.7±5.2                     | 6.2±5.1                     | 6.8±5.2                     | 0.19                       |
| Duration from onset to diagnosis (month) | 33.0±30.8              | 31.2±24.6                   | 33.3±31.8                   | 0.39                       |
| Dementia severity and clinical variables | \[-1.8±4.5\]               | \[-2.9±4.7\]               | \[-1.6±4.4\]               | <0.01*                     |
| Annual MMSE score change    | \[1.9±3.1\]                | \[3.5±3.9\]                | \[1.6±2.9\]                | <0.01*                     |
| Annual CDR-SB score change  | \[1.8±18.0\]               | \[4.2±22.0\]               | \[1.4±17.1\]               | 0.18                       |
| GDS score                   | 6.7±4.3                     | 6.6±4.5                     | 6.8±4.3                     | 0.64                       |
| Comorbidities               |                            |                            |                            |                            |
| Hypertension                | 411 (50.4)                  | 61 (46.9)                   | 350 (51.0)                  | 0.39                       |
| Diabetes mellitus           | 187 (22.9)                  | 34 (26.2)                   | 153 (22.3)                  | 0.33                       |
| Cardiovascular disease      | 121 (14.8)                  | 18 (13.9)                   | 103 (15.0)                  | 0.73                       |
| Stroke                      | 62 (7.6)                    | 10 (7.7)                    | 52 (7.6)                    | 0.96                       |
| Alcohol consumption         |                            |                            |                            |                            |
| Current                     | 515 (79.7)                  | 96 (86.5)                   | 419 (78.3)                  | 0.05                       |
| Never                       | 131 (20.3)                  | 15 (13.5)                   | 116 (21.7)                  | 0.56                       |
| Smoking                     |                            |                            |                            |                            |
| Current smoker              | 56 (8.7)                    | 7 (6.3)                     | 49 (9.2)                    |                            |
| Ex-smoker                   | 123 (19.0)                  | 20 (18.0)                   | 103 (19.3)                  |                            |
| Never smoked                | 467 (72.3)                  | 84 (75.7)                   | 383 (71.6)                  |                            |
| Living with main caregiver  | 490 (60.2)                  | 72 (55.8)                   | 418 (61.0)                  | 0.26                       |
| Medication usage (MPR)      |                            |                            |                            |                            |
| Antipsychotics              | 0.2±0.4                     | 0.4±0.4                     | 0.2±0.3                     | <0.01*                     |
| Benzodiazepines             | 0.3±0.4                     | 0.3±0.4                     | 0.3±0.4                     | 0.80                       |
| Galantamine                 | 0.3±0.4                     | 0.3±0.4                     | 0.3±0.4                     | 0.77                       |
| Rivastigmine                | 0.4±0.4                     | 0.4±0.4                     | 0.4±0.4                     | 0.92                       |
| Donepezil                   | 0.6±0.4                     | 0.6±0.4                     | 0.6±0.4                     | 0.48                       |
| Memantine                   | 0.2±0.3                     | 0.3±0.4                     | 0.2±0.3                     | 0.05                       |

Data are mean±standard-deviation or \(n\) values.

*\(p<0.05\) between institutionalized and not-institutionalized patients.

CDR-SB: Clinical Dementia Rating Sum of Boxes, GDS: Geriatric Depression Scale, MMSE: Mini Mental State Examination, MPR: medication possession ratio, NPI: NeuroPsychiatric Inventory.
line characteristics among all 2,470 patients revealed that lower MMSE and higher NPI scores at baseline were independent risk factors for institutionalization. Other baseline variables such as age, length of formal education, CDR-SB score, comorbidities, alcohol consumption, smoking, and the relationship with the main caregiver were not significantly related to patient institutionalization. Whether the patient was taking a medication at baseline such as ChEI, memantine, antipsychotic, or benzodiazepine also did not significantly influence institutionalization (Table 3). However, in the sensitivity analysis, a higher CDR score was an independent risk factor for institutionalization (relative to CDR score=0.5: HR=1.79, 95% CI=1.335–2.332, and \( p < 0.01 \) for CDR score=1; and HR=1.68, 95% CI=1.120–2.533, and \( p = 0.0123 \) for CDR score=2). In the multivariate Cox proportional-hazards model with baseline characteristics among the 1,456 patients with APOE genotyping, the presence of the APOE e4 allele did not predict earlier institutionalization (\( p = 0.723 \)) (Table 3). In the multivariate Cox proportional-hazards model with variables that were measured longitudinally (816 patients), larger annual change in CDR-SB score (HR=1.15, \( p < 0.001 \)) and higher MPR of antipsychotics (HR=1.89, \( p = 0.005 \)) predicted a shorter time to when institutionalization would be necessary (Table 4).

**DISCUSSION**

This study found that lower MMSE score, higher CDR score, and higher NPI score at baseline were independent risk factors for institutionalization. Other baseline variables such as age, length of formal education, CDR-SB score, comorbidities, alcohol consumption, smoking, and the relationship with the main caregiver were not significantly related to patient institutionalization. Whether the patient was taking a medication at baseline such as ChEI, memantine, antipsychotic, or benzodiazepine also did not significantly influence institutionalization (Table 3). However, in the sensitivity analysis, a higher CDR score was an independent risk factor for institutionalization (relative to CDR score=0.5: HR=1.79, 95% CI=1.335–2.332, and \( p < 0.01 \) for CDR score=1; and HR=1.68, 95% CI=1.120–2.533, and \( p = 0.0123 \) for CDR score=2). In the multivariate Cox proportional-hazards model with baseline characteristics among the 1,456 patients with APOE genotyping, the presence of the APOE e4 allele did not predict earlier institutionalization (\( p = 0.723 \)) (Table 3). In the multivariate Cox proportional-hazards model with variables that were measured longitudinally (816 patients), larger annual change in CDR-SB score (HR=1.15, \( p < 0.001 \)) and higher MPR of antipsychotics (HR=1.89, \( p = 0.005 \)) predicted a shorter time to when institutionalization would be necessary (Table 4).

**Table 3. Predictors of institutionalization among baseline characteristics at the diagnosis obtained using multivariate Cox proportional-hazards models**

| Variables                              | Model 1 (n=2,470) | Model 2 (n=1,456) |
|----------------------------------------|-------------------|-------------------|
|                                        | HR    | 95% CI | \( p \)  | HR    | 95% CI | \( p \)  |
| Age                                    | 1.01  | 0.99–1.02 | 0.21  | 1.00  | 0.98–1.02 | 0.65  |
| Male                                   | 0.83  | 0.58–1.16  | 0.28  | 0.86  | 0.52–1.41  | 0.54  |
| Education                              | 1.01  | 0.98–1.04  | 0.31  | 1.02  | 0.98–1.06  | 0.28  |
| Dementia severity and clinical variables|       |         |       |       |         |       |
| MMSE score                             | 0.95  | 0.92–0.97  | <0.01* | 0.92  | 0.88–0.95  | <0.01* |
| CDR-SB score                           | 1.04  | 0.99–1.09  | 0.05  | 1.03  | 0.96–1.09  | 0.44  |
| NPI score                              | 1.01  | 1.00–1.01  | <0.01* | 1.01  | 1.00–1.01  | 0.02*  |
| GDS score                              | 0.98  | 0.95–1.00  | 0.08  | 1.00  | 0.96–1.03  | 0.98  |
| Comorbidities                          |       |         |       |       |         |       |
| Hypertension                           | 0.84  | 0.66–1.04  | 0.12  | 0.78  | 0.56–1.07  | 0.13  |
| Diabetes mellitus                      | 1.15  | 0.88–1.48  | 0.29  | 1.10  | 0.75–1.60  | 0.62  |
| Cardiovascular disease                 | 0.83  | 0.59–1.14  | 0.25  | 0.79  | 0.48–1.29  | 0.35  |
| Stroke                                 | 0.78  | 0.51–1.17  | 0.23  | 0.72  | 0.35–1.43  | 0.35  |
| Alcohol consumption (current)          | 1.20  | 0.89–1.60  | 0.23  | 1.68  | 1.08–2.61  | 0.02*  |
| Smoking                                |       |         |       |       |         |       |
| Current smoker                         | 1.14  | 0.72–1.48  | 0.57  | 1.41  | 0.77–2.57  | 0.26  |
| Ex-smoker                              | 1.23  | 0.88–1.71  | 0.21  | 1.36  | 0.85–2.16  | 0.19  |
| Never smoked                           | 1.00  |          |       | 1.00  |          |       |
| Living with main caregiver             | 0.90  | 0.70–1.15  | 0.40  | 1.10  | 0.77–1.58  | 0.59  |
| Main caregiver                         |       |         |       |       |         |       |
| Spouse                                 | 1.00  |          |       | 1.00  |          |       |
| Son/daughter-in-law                    | 1.08  | 0.77–1.50  | 0.65  | 1.03  | 0.65–1.62  | 0.88  |
| Daughter/son-in-law                    | 0.87  | 0.60–1.24  | 0.44  | 1.07  | 0.64–1.76  | 0.78  |
| Others                                 | 1.67  | 0.95–2.91  | 0.07  | 2.23  | 0.99–4.99  | 0.05  |
| Medications                            |       |         |       |       |         |       |
| ChEI/memantine                         | 1.21  | 0.86–1.67  | 0.26  | 1.11  | 0.69–1.78  | 0.65  |
| Antipsychotic                          | 1.26  | 0.91–1.73  | 0.16  | 1.33  | 0.82–2.12  | 0.24  |
| Benzodiazepine                         | 0.97  | 0.77–1.21  | 0.81  | 0.97  | 0.70–1.32  | 0.82  |
| APOE e4 carrier                        | 0.95  | 0.69–1.28  | 0.72  |       |         |       |

*\( p < 0.05 \) for the risk of institutionalization.

APOE: apolipoprotein E, CDR-SB: Clinical Dementia Rating Sum of Boxes, ChEI: cholinesterase inhibitors, CI: confidence interval, GDS: Geriatric Depression Scale, HR: hazard ratio, MMSE: Mini Mental State Examination, NPI: Neuropsychiatric Inventory.
Table 4. Predictors of institutionalization including variables that were measured longitudinally obtained using a multivariate Cox proportional-hazards model with 816 patients

| Variables                         | HR    | 95% CI          | p    |
|----------------------------------|-------|-----------------|------|
| Age                              | 1.02  | 0.99-1.04       | 0.21 |
| Male                             | 1.28  | 0.70-2.29       | 0.41 |
| Education                        | 0.98  | 0.93-1.02       | 0.26 |
| Duration from onset to diagnosis | 1.00  | 0.99-1.00       | 0.73 |
| Dementia severity and clinical variables |       |                 |      |
| Annual MMSE score change         | 1.02  | 0.96-1.07       | 0.45 |
| Annual CDR-SB score change       | 1.15  | 1.06-1.23       | <0.01*|
| Annual NPI score change          | 1.00  | 0.98-1.01       | 0.34 |
| Smoking                          |       |                 |      |
| Current smoker                   | 0.59  | 0.24-1.38       | 0.22 |
| Ex-smoker                        | 0.96  | 0.51-1.77       | 0.90 |
| Never smoked                     | 1.00  |                 |      |
| Medication usage (MPR)           |       |                 |      |
| Antipsychotics                   | 1.89  | 1.20-2.97       | <0.01*|
| Benzodiazepines                  | 0.67  | 0.40-1.12       | 0.12 |
| Galantamine                      | 0.88  | 0.55-1.39       | 0.59 |
| Rivastigmine                     | 0.95  | 0.60-1.50       | 0.83 |
| Donepezil                        | 0.96  | 0.60-1.52       | 0.87 |
| Memantine                        | 1.15  | 0.72-1.83       | 0.55 |

*p<0.05 for the risk of institutionalization.

CDR-SB: Clinical Dementia Rating Sum of Boxes, CI: confidence interval, HR: hazard ratio, MMSE: Mini Mental State Examination, MPR: medication possession ratio, NPI: Neuropsychiatric Inventory.

and higher NPI score at baseline, larger annual change in CDR-SB score, and more-frequent usage of antipsychotic drugs were independent predictors of earlier institutionalization. Factors such as APOE genotype and the relationship with the main caregiver did not predict institutionalization.

We found that 17.0% of patients were institutionalized in either nursing homes or long-term-care hospitals at a mean of 3.19 years during the follow-up in our study. This is a smaller proportion than in previous reports. In the systematic review by Luppa et al., approximately 20% of patients were institutionalized within the first year following a diagnosis of dementia. This interstudy difference may be due to cultural differences between Asia (and especially South Korea) and western countries. Korean caregivers show a higher level of familism than do white American caregivers. Due to the Confucian attitude of having respect for one's elders, a significant proportion of Korean caregivers are likely to feel guilty about institutionalizing their spouse or parents. This makes them more willing to care for a dementia patient even when the patient demonstrates chronic and severe dysfunction in the activities of daily living (ADL).

Among baseline characteristics at the time of diagnosis, lower MMSE score and higher CDR and NPI scores at baseline were independent predictors of earlier institutionalization. These findings are consistent with those of previous studies. However, unlike previous reports of being female increasing the likelihood of being admitted to a nursing home, the current study found that gender was not related to the rate of inpatient institutionalization, which is consistent with the results of recent studies carried out in Australia.

The presence of the APOE e4 allele did not predict institutionalization in this study, which is consistent with a previous study. The APOE e4 allele is a well-known risk factor for the development of AD, but its effect on the progression of this disease remains unresolved. A few studies have found seemingly deleterious effects of the APOE e4 genotype on disease progression, but most studies have found no definite correlation between APOE genotype and the progression of the disease. One study even found that the progression of the disease was more aggressive in patients who lack the APOE e4 allele. The findings of the current study are therefore consistent with previous reports that the APOE e4 allele is associated with earlier development of AD but not with the disease progression.

Among predictors that measured longitudinal changes, more-rapid decline in the severity of the dementia (CDR-SB) and more-frequent use of antipsychotic drugs were considered independent risk factors leading to earlier institutionalization. In a recent study involving a sample population that included various types of dementia, greater declines in cognitive abilities (MMSE score) and functional abilities [as measured using the SMAF (Functional Autonomy Measurement System)] were associated with earlier institutionalization. However, other studies where the sample population was confined to patients with AD found that the rate of change in instrumental ADL decline was probably an independent predictor of earlier institutionalization, although a rapid decrease in MMSE score was also a significant predictor of institutionalization in univariate analysis. The current study findings are considered to be essentially in agreement with these findings, in that institutionalized patients exhibited a higher decrease in MMSE scores, but a decline in overall dementia severity (CDR-SB) remained the more important predictor. These findings may be due to differences between various types of dementia. A study that employed a functional measure of severity (CDR) in patients with AD and frontotemporal dementia (FTD) who were matched for age and MMSE score found that the total
CDR-SB score was significantly worse in those with FTD than in patients with AD. This means that when a study population is homogeneous, the MMSE scores may be more strongly correlated with CDR-SB score, resulting in a decrease in the MMSE score not being an independent predictor. Furthermore, to the best of our knowledge, no studies searching for predictors of institutionalization have included CDR-SB in their analyses. In our study the annual change in the CDR-SB score was a significant independent predictor, whereas the CDR-SB score at the diagnosis of AD was not.

This study was subject to some limitations. The dynamic nature of the CREDOS cohort meant that the follow-up periods differed between the patients, making it impossible to know the proportion of institutionalized subjects during a specific time period. Furthermore, APOE genotyping and follow-up tests were performed in only some of the included patients, and we used three data sets with different numbers of subjects. The three models with different numbers of subjects revealed differences in the demographic characteristics, although these differences did not affect the main results. In addition, we regarded a patient as having been formally admitted into a long-term-care hospital when he or she stayed in the same facility for at least 6 months. This 6-month cutoff period was arbitrary, and there might have been some patients who were discharged after staying in the same hospital for more than 6 months. Furthermore, previous studies have found factors such as the caregiver age, caregiving burden, health status, and stress level of the caregivers to be predictors of the earlier institutionalization of patients. However, the lack of sufficient information from caregiver questionnaires meant that various potentially important caregiver factors could not be included or considered in this study. In addition, both the physical and instrumental ADL could be predictors of earlier institutionalization, but ADL scores were not included in the present analyses. Finally, the follow-up tests involved a relatively small proportion of the patient cohort (33.0%, 816 out of 2,470), and so a separate analysis was needed for variables that exhibited longitudinal changes.

This study found that among patients with AD, those with lower cognitive ability, higher dementia severity, and more severe behavioral symptoms at baseline were more likely to be institutionalized earlier during the course of the disease. More-rapid cognitive decline in the severity of the dementia and more-frequent use of antipsychotic drugs during follow-up were independent indicators of earlier institutionalization. This information will allow clinicians to make more-practical and informed choices regarding treatment options, and assist caregivers in the appropriate management of specific patients.

Conflicts of Interest

The authors have no financial conflicts of interest.

Acknowledgements

This study was supported by grants from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (grant no. HI10C2020) and the Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (grant no. 2014M3C7A1064752).

REFERENCES

1. Agüero-Torres H, von Strauss E, Viitanen M, Winblad B, Fratiglioni L. Institutionalization in the elderly: the role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol 2001;54:795-801.
2. Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von Strauss E, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health 1998;88:1452-1456.
3. Luppa M, Luck T, Brähler E, König HH, Riedel-Heller SG. Prediction of institutionalisation in dementia. A systematic review. Dement Geriatr Cogn Disord 2008;26:65-78.
4. Caldwell L, Low LF, Brodaty H. Caregivers’ experience of the decision-making process for placing a person with dementia into a nursing home: comparing caregivers from Chinese ethnic minority with those from English-speaking backgrounds. Int Psychogeriatr 2014;26:413-424.
5. Gaugler JE, Duval S, Anderson KA, Kane RL. Predicting nursing home admission in the U.S: a meta-analysis. BMC Geriatr 2007;7:13.
6. Gaugler JE, Yu F, Krichbaum K, Wyman JF. Predictors of nursing home admission for persons with dementia. Med Care 2009;47:191-198.
7. Kim JM, Shin IS, Jeong SJ, Gormley N, Yoon JS. Predictors of institutionalization in patients with dementia in Korea. Int J Geriatr Psychiatry 2002;17:101-106.
8. Luppa M, Luck T, Weyerer S, König HH, Brähler E, Riedel-Heller SG. Prediction of institutionalization in the elderly: A systematic review. Age Ageing 2010;39:31-38.
9. Wattino C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist 2011;51:17-27.
10. Hébert R, Dubois MF, Wolfson C, Chambers L, Cohen C. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 2001;56:M693-M699.
11. Gaugler JE, Kane RL, Kane RA, Clay T, Newcomer R. Caregiving and institutionalization of cognitively impaired older people: utilizing dynamic predictors of change. Gerontologist 2003;43:219-229.
12. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090-2097.
13. Park HK, Na DL, Han SH, Kim JY, Cheong HK, Kim SY, et al. Clinical characteristics of a nationwide hospital-based registry of mild-to-moderate Alzheimer’s disease patients in Korea: a CREDOS (Clinical Research Center for Dementia of South Korea) study. J Korean Med Sci 2011;26:1219-1226.
14. Lee M, Lim TS, Lee HY, Moon SY. Profile of memory impairment as a prognostic marker in amnestic mild cognitive impairment. J Neurol Sci 2014;347:124-128.
15. Moon SY, Na DL, Seo SW, Lee JY, Ku BD, Kim SY, et al. Impact of white matter changes on activities of daily living in mild to moderate dementia.
dementia. Eur Neurol 2011;65:223–230.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Seok JE. Public long-term care insurance for the elderly in Korea: design, characteristics, and tasks. Soc Work Public Health 2010;25:185-209.
18. Park IS, Kim SK. Korean elderly long-term care insurance system and long-term care hospital. J Korean Geriat Soc 2008;12:68-73.
19. Kang IO, Park CY, Lee Y. Role of healthcare in Korean long-term care insurance. J Korean Med Sci 2012;27 Suppl:S41-S46.
20. Kwon S. The introduction of long-term care insurance in South Korea. Eurohealth 2009;15:28-29.
21. Youn G, Knight BG, Jeong HS, Benton D. Differences in familism values and caregiving outcomes among Korean, Korean American, and White American dementia caregivers. Psychol Aging 1999;14:355-364.
22. Kim MD, Hong SC, Lee CI, Kim SY, Kang IO, Lee SY. Caregiver burden among caregivers of Koreans with dementia. Gerontology 2009;55:106-113.
23. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
24. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC, et al. Accelerated decline in apolipoprotein E epsilon 4 homozygotes with Alzheimer's disease. Neurology 1998;51:149-153.
25. Dal Forno G, Rasmusson DX, Brandt J, Carson KA, Brookmeyer R, Troncoso J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996;53:345-350.
26. Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, et al. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 1999;267:65-68.
27. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47:444-448.
28. Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, Van Broeckhoven C, Breteler MM, et al. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol 1999;246:304-308.
29. Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein epsilon 4 allele and disease progression in patients with later-onset Alzheimer's disease. Neurosci Lett 1999;183:32-34.
30. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998;55:1065-1069.
31. Stern Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-620.
32. Rosen HJ, Narvaez JM, Hallam B, Kramer JH, Wyss-Coray C, Gearhart R, et al. Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia. Alzheimer Dis Assoc Disord 2004;18:202-207.